Since their release into the market in 1989, proton pump inhibitors (PPIs) have marked a before and after in the treatment of illnesses linked to stomach acid. Owing to a unique, extremely efficient method of action that prevents parietal cells from obstructing the last convergent stage of stomach acid production, as well as a small number of, generally manageable side effects. Due to their rapid efficacy in treating peptic ulcer disease, gastroesophageal ulcers, ZollingerEllison syndrome, nonsteroidal anti-inflammatory drug-associated ulcers, and the elimination of Helicobacter pylori, these drugs quickly replaced other pharmacological substances like H2 antagonists as the preferred treatment option. This has resulted in an exponential rise in their prescription up to this point. Nevertheless, there is growing evidence of long-term negative consequences from the frequent use of PPIs, including an increased risk of dementia, enteroendocrine cancers, liver, renal, and cardiovascular disease.